Log in
Enquire now

Clinical Studies Sponsored by Emergent BioSolutions

Clinical Studies Sponsored by Emergent BioSolutions
Clinical Studies Sponsored by Edwards Lifesciences
Clinical Studies Sponsored by Nektar Therapeutics
Clinical Studies Sponsored by Amicus Therapeutics
CEOs of voicification companies
CEOs of unit testing companies
Clinical Studies where
Trial Sponsor
is
Name
Description
NCT Number
Health Conditions in Trial
Clinical Trial Start Date
Study Completion Date
Clinical Trial Study Type
‌
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)

NCT00928577
Smallpox
Smallpox
2008
2015
Observational
‌
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults

NCT01491607
Anthrax
Anthrax
2011
2012
Interventional
‌
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel

NCT01540929
Smallpox
Smallpox
2009
2012
Observational
‌
ACAM2000® Myopericarditis Registry

NCT01395082
Myocarditis
Myocarditis
Pericarditis
Pericarditis
2011
February 4, 2019
Observational
‌
Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)

NCT01202695
Anthrax
Anthrax
2010
2011
Interventional
‌
Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum

NCT00448253
2007
2008
Interventional
‌
Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)

NCT03624946
June 27, 2018
March 6, 2019
Interventional
‌
Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults

NCT05935917
Smallpox
Smallpox
May 30, 2023
September 27, 2023
Interventional
‌
Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax

NCT03569514
Anthrax
Anthrax
February 11, 2024
2025
Observational
‌
A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients

NCT03569553
February 11, 2024
2025
Observational
‌
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

NCT04661839
COVID-19
COVID-19
December 24, 2020
July 27, 2021
Interventional
‌
BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin

NCT02055183
Botulism
Botulism
2014
2017
Observational
‌
VELOCITY: An Anthrax Vaccine Clinical Study

NCT03877926
‌
Anthrax
March 11, 2019
August 6, 2020
Interventional
‌
Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

NCT00845650
Anthrax
Anthrax
2009
2010
Interventional
‌
VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV

NCT01158157
September 13, 2010
February 14, 2012
Interventional
‌
A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines

NCT01979406
2013
2015
Interventional
‌
Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses

NCT00360737
‌
Healthy
2006
2010
Interventional
‌
Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects

NCT02061358
2014
2015
Interventional
‌
Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults

NCT05377255
Opioid overdose
Opioid overdose
March 28, 2022
May 10, 2022
Interventional
‌
Ciprofloxacin BioThrax Co-Administration Study

NCT01753115
‌
Anthrax
2012
2013
Interventional
‌
Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

NCT00053482
Smallpox
Smallpox
2003
2003
Interventional
‌
Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

NCT00053495
Smallpox
Smallpox
2003
2003
Interventional
‌
A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

NCT03160339
May 1, 2017
November 27, 2017
Interventional
‌
Study to Evaluate the Safety and Immunogenicity of Orally-administered HIV Vaccine in Healthy, HIV-uninfected Adult Participants

NCT02771730
HIV vaccine
HIV vaccine
2015
2019
Interventional
‌
Clinical Benefit, Safety and PK of Raxibacumab in Subjects Exposed to Bacillus Anthracis

NCT02177721
2021
2025
Interventional
Results per page:
37 results
0 selected
37 results
0 selected
Golden logo

Company

  • Home
  • Pricing
  • Become an Editor
  • Enterprise

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us

Explore companies

  • Artificial Intelligence
  • Fintech
  • Biotechnology
  • Cybersecurity
  • Semiconductors
  • Electric Vehicles
  • Cloud Computing
  • Robotics
  • SaaS
  • Renewable Energy
  • Venture Capital
  • Blockchain
  • Browse all →